Schlumberger NV vs TransMedics Group Inc — how do they compare? Schlumberger NV trades at $46.39 (market cap $69.36B), while TransMedics Group Inc trades at $74.3 (market cap $2.54B). The key difference: Schlumberger NV is far larger — about 27.3× TransMedics Group Inc's market cap, and Schlumberger NV pays a 2.54% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| SLB | TMDX | |
|---|---|---|
Market Cap | $69.36B | $2.54B |
Sector | Energy | Technology |
52-Week High | $58.01 | $150.42 |
52-Week Low | $31.72 | $61.99 |
Enterprise Value | $77.58B | $2.94B |
Dividend Yield | 2.54% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
TransMedics (TMDX) trades at $73.47, down 0.69% with neutral technical signals. The stock shows strong profitability with 27% net margins and 45% ROE, though Q1 2026 earnings missed expectations. Recent strategic investment in European aviation logistics aims to expand the Organ Care System platform. Analyst consensus remains bullish with a $108.71 price target representing 48% upside potential.
Long-term growth prospects appear solid given TMDX's expanding transplant ecosystem, but near-term margin pressure from expansion investments and execution risks warrant caution. The company maintains competitive advantages in organ transplant logistics, though increased spending and competitive threats from alternatives like Strata Critical Medical present headwinds for shareholder returns.
Trailing returns across standard periods
Latest headlines on both assets
Schlumberger is the largest oilfield service firm in the world, with expertise in myriad disciplines, including reservoir performance, well construction, production enhancement, and more recently, digital solutions. It maintains a reputation as one of the industry's leading innovators, which has earned it dominant share in numerous end markets.
Read more on SLB →TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →